Welcome to our dedicated page for Certara SEC filings (Ticker: CERT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Problem: Certara’s model-informed drug development business packs pages of dense biosimulation jargon, multi-year SaaS contracts, and equity-based incentives into every disclosure. If you have ever searched for “Certara SEC filings explained simply” or tried to trace “Certara insider trading Form 4 transactions,” you know how time-consuming that can be.
Solution: Stock Titan’s AI reads each Certara annual report 10-K, Certara quarterly earnings report 10-Q filing, and Certara 8-K material events explained within minutes—so you don’t have to. Our platform delivers:
- AI-powered summaries that translate technical pharmacokinetic language into plain English
- Real-time alerts on Certara Form 4 insider transactions—never miss executive stock moves
- Side-by-side earnings report filing analysis that highlights SaaS subscription growth, consulting margins, and backlog trends
- Complete coverage of every form, from S-8 equity plans to the proxy statement executive compensation tables
Results: Monitor “Certara Form 4 insider transactions real-time,” compare revenue recognition notes across periods, or dive into “understanding Certara SEC documents with AI” in one workspace. Need governance details? Our tool surfaces board pay straight from the “Certara proxy statement executive compensation” section. Curious about future milestones? Material events in 8-K filings are flagged alongside modeling pipeline updates. Whether you are tracking “Certara earnings report filing analysis” before an FDA catalyst or auditing share repurchase disclosures, Stock Titan equips professionals with the clarity, speed, and confidence to act on Certara’s data-rich filings.
Form 144 filing for Certara, Inc. (CERT): The filer intends to sell 51,224 shares of common stock through Fidelity Brokerage Services on 09/09/2025, with an aggregate market value of $559,303.56. These shares represent restricted stock that vested on 09/09/2020 and were acquired as compensation from the issuer. The company reports 160,623,580 shares outstanding. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that they are not aware of any undisclosed material adverse information.
Wasatch Advisors LP reported beneficial ownership of 13,532,882 shares of Certara common stock, representing 8.3% of the class. The filer discloses sole dispositive power over all 13,532,882 shares and sole voting power on 9,969,332 shares, and states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control.
This disclosure meets the >5% reporting threshold for institutional investors and notifies the market of a material passive stake in Certara without indicating any plans to seek control.
FAQ
What is the current stock price of Certara (CERT)?
What is the market cap of Certara (CERT)?
